Literature DB >> 16934338

Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment.

Jack Antel1, Amit Bar-Or.   

Abstract

Immunoglobulins (Igs) have long been implicated in contributing to the disease course of multiple sclerosis (MS). The earliest and perhaps still most consistent abnormal immunologic laboratory finding in MS is the increased concentration of Ig in the CSF, representing intrathecal antibody synthesis. Analysis of CSF Ig in terms of rate of production and restricted diversity (oligoclonal bands) remains a supportive diagnostic criteria for MS. Despite large-scale studies such as the analysis of 1000 cases reported by Ebers and Paty [Ebers, G.C., Paty, D.W., 1980. CSF electrophoresis in one thousand patients. Can. J. Neurol. Sci. 7 (4) 275-280], the challenge of correlating CSF Ig profiles and specific disease phenotypes remains. More recently, evidence from animal models and several human studies suggests that antibody-independent functions of B cells may also be implicated in the pathogenesis of MS. This presentation considers what roles Ig and/or B cells can play in mediating or regulating disease-relevant immune responses in MS. A timely corollary is whether B cell/Ig-directed therapeutic strategies can be effective in MS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16934338     DOI: 10.1016/j.jneuroim.2006.06.032

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  26 in total

Review 1.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

2.  MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencing.

Authors:  William H Rounds; Edward A Salinas; Tom B Wilks; Mikhail K Levin; Ann J Ligocki; Carolina Ionete; Carlos A Pardo; Steven Vernino; Benjamin M Greenberg; Douglas W Bigwood; Eric M Eastman; Lindsay G Cowell; Nancy L Monson
Journal:  Gene       Date:  2015-07-11       Impact factor: 3.688

3.  Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins.

Authors:  Simone M Brändle; Birgit Obermeier; Makbule Senel; Jessica Bruder; Reinhard Mentele; Mohsen Khademi; Tomas Olsson; Hayrettin Tumani; Wolfgang Kristoferitsch; Friedrich Lottspeich; Hartmut Wekerle; Reinhard Hohlfeld; Klaus Dornmair
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-20       Impact factor: 11.205

4.  The structural and functional role of myelin fast-migrating cerebrosides: pathological importance in multiple sclerosis.

Authors:  Maria Podbielska; Steven B Levery; Edward L Hogan
Journal:  Clin Lipidol       Date:  2011-04

Review 5.  beta2-integrins in demyelinating disease: not adhering to the paradigm.

Authors:  Xianzhen Hu; Jillian E Wohler; Kari J Dugger; Scott R Barnum
Journal:  J Leukoc Biol       Date:  2009-12-09       Impact factor: 4.962

Review 6.  The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration.

Authors:  Jessy John Alexander; Aileen Judith Anderson; Scott Robert Barnum; Beth Stevens; Andrea Joan Tenner
Journal:  J Neurochem       Date:  2008-10-24       Impact factor: 5.372

Review 7.  Vaccines for multiple sclerosis: progress to date.

Authors:  Jorge Correale; Mauricio Farez; Wendy Gilmore
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 8.  Development of oral cladribine for the treatment of multiple sclerosis.

Authors:  Hans-Peter Hartung; Orhan Aktas; Bernd Kieseier; Giancarlo Comi Giancarlo Comi
Journal:  J Neurol       Date:  2010-02       Impact factor: 4.849

9.  Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis.

Authors:  Elizabeth M Cameron; Sade Spencer; Jonathan Lazarini; Christopher T Harp; E Sally Ward; Mark Burgoon; Gregory P Owens; Michael K Racke; Jeffrey L Bennett; Elliot M Frohman; Nancy L Monson
Journal:  J Neuroimmunol       Date:  2009-07-24       Impact factor: 3.478

10.  B cells and monocytes from patients with active multiple sclerosis exhibit increased surface expression of both HERV-H Env and HERV-W Env, accompanied by increased seroreactivity.

Authors:  Tomasz Brudek; Tove Christensen; Lars Aagaard; Thor Petersen; Hans J Hansen; Anné Møller-Larsen
Journal:  Retrovirology       Date:  2009-11-16       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.